Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus PAZOPANIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus PAZOPANIB HYDROCHLORIDE.
CAPRELSA vs PAZOPANIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-Kit). It also inhibits other kinases such as fibroblast growth factor receptors (FGFR-1, -3), cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor (c-Fms).
300 mg orally once daily, with or without food.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Do not crush tablets.
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Terminal half-life is approximately 31 hours, supporting once-daily dosing.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily fecal (83%), with renal elimination accounting for <4% of the administered dose.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor